Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma

BACKGROUND: High-grade serous ovarian cancer is a detrimental disease. Treatment options in patients with a recurrent disease are dependent on BRCA1/2 mutation status since only patients with known BRCA mutation are eligible for treatment with poly(ADP-ribose) polymerase inhibitors (PARPi). The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Gornjec, Andreja, Novakovic, Srdjan, Stegel, Vida, Hocevar, Marko, Pohar Marinsek, Ziva, Gazic, Barbara, Krajc, Mateja, Skof, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444857/
https://www.ncbi.nlm.nih.gov/pubmed/30940100
http://dx.doi.org/10.1186/s12885-019-5535-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444857/
https://www.ncbi.nlm.nih.gov/pubmed/30940100
http://dx.doi.org/10.1186/s12885-019-5535-2

Ejemplares similares